Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Craig H. Moskowitz, Jan Walewski, Tamás Masszi et al.|The Lancet|2015

Cited by 740